CA2130787A1 - Ursodeoxycholic acid-containing medicament in a liquid administration form - Google Patents
Ursodeoxycholic acid-containing medicament in a liquid administration formInfo
- Publication number
- CA2130787A1 CA2130787A1 CA002130787A CA2130787A CA2130787A1 CA 2130787 A1 CA2130787 A1 CA 2130787A1 CA 002130787 A CA002130787 A CA 002130787A CA 2130787 A CA2130787 A CA 2130787A CA 2130787 A1 CA2130787 A1 CA 2130787A1
- Authority
- CA
- Canada
- Prior art keywords
- active agent
- ursodeoxycholic acid
- administration form
- infants
- liquid administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Abstract
The active agent ursodeoxycholic acid has proved therapeutically active in infants, inter alia for the treatment of cholestatic hepatic diseases. A problem when administering this active agent, a bile acid, to infants is its extreme bitterness. As a result of the present invention a taste-acceptable, liquid administration form for ursodeoxycholic acid with an adequately high active agent concentration is described. The liquid to be ingested is a suspension prepared accompanied by the addition of a swelling and/or thickening agent, which contains the active agent mainly in fine crystalline form as the disperse phase and only in a much smaller proportion dissolved in the aqueous dispersant. A remaining residual bitterness can be additionally masked by the addition of .beta. -cyclodextrin or suitable taste correcting agents.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH2567/93-2 | 1993-08-30 | ||
CH256793 | 1993-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2130787A1 true CA2130787A1 (en) | 1995-03-01 |
CA2130787C CA2130787C (en) | 2006-12-05 |
Family
ID=4236712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002130787A Expired - Fee Related CA2130787C (en) | 1993-08-30 | 1994-08-24 | Ursodeoxycholic acid-containing medicament in a liquid administration form |
Country Status (8)
Country | Link |
---|---|
US (1) | US5534505A (en) |
EP (1) | EP0640344B1 (en) |
JP (1) | JP3631782B2 (en) |
AT (1) | ATE171874T1 (en) |
CA (1) | CA2130787C (en) |
DE (1) | DE59407041D1 (en) |
DK (1) | DK0640344T3 (en) |
ES (1) | ES2121599T3 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2208497A1 (en) | 2009-01-15 | 2010-07-21 | Charité-Universitätsmedizin Berlin (Charité) | Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1113785B1 (en) * | 1998-07-24 | 2005-04-13 | Seo Hong Yoo | Clear aqueous solutions of bile acids |
US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US7772220B2 (en) * | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
EP1255566A2 (en) * | 2000-02-04 | 2002-11-13 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
EP1147779B1 (en) * | 2000-04-20 | 2006-05-31 | BIOPROGRESS S.p.A. | A method for rendering ursodeoxycholic acid in soluble form pharmaceutical compositions |
US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
WO2005042026A1 (en) * | 2003-10-31 | 2005-05-12 | Wakamoto Pharmaceutical Co., Ltd. | Water-based composition undergoing reversible thermogelation |
ATE464883T1 (en) * | 2004-07-22 | 2010-05-15 | Bend Res Inc | FLAVOR-COVERING FORMULATION WITH A RETARDED-RELEASE INGREDIENT FORMULATION AND/OR QUICKLY SOLUBLE CYCLODEXTRIN |
ES2339790T3 (en) * | 2004-08-30 | 2010-05-25 | Seo Hong Yoo | NEUOPROTECTOR EFFECT OF UDCA SOLUBILIZED IN FOCAL ISCHEMICAL MODEL. |
ATE506955T1 (en) * | 2004-10-15 | 2011-05-15 | Seo Hong Yoo | COMPOSITIONS FOR REDUCING THE TOXICITY OF CISPLATIN, CARBOPLATIN AND OXALIPLATIN |
CA2585471A1 (en) * | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
JP2010503667A (en) * | 2006-09-15 | 2010-02-04 | ホン ユー,ソ | Bile preparation for colorectal disease |
GB0817969D0 (en) * | 2008-10-01 | 2008-11-05 | Axcess Ltd | Pharmaceutical composition |
BR112014010223B8 (en) * | 2011-10-28 | 2021-02-23 | Lumena Pharmaceuticals Llc | use of a composition comprising bile acid recycling inhibitors and pediatric dosage form |
US10016357B2 (en) * | 2012-03-22 | 2018-07-10 | The Beauty Factory, Llc | Personal lubricants |
MX2014016022A (en) | 2013-06-21 | 2015-08-13 | Dode S A | Collapsible container. |
WO2016019066A1 (en) * | 2014-07-29 | 2016-02-04 | University Of Tennessee Research Foundation | Composition and method for treating liver disease |
WO2021099973A1 (en) | 2019-11-22 | 2021-05-27 | Shilpa Medicare Limited | Injectable compositions of ursodeoxycholic acid |
CN115068418B (en) * | 2022-07-20 | 2022-10-28 | 奥信阳光(北京)药业科技有限公司 | Ursodeoxycholic acid oral solution and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639597A (en) * | 1968-02-02 | 1972-02-01 | Merck & Co Inc | Pharmaceutical compositions containing cholanic acid conjugates |
DE2757641C2 (en) * | 1977-12-23 | 1980-03-06 | Rowa Ltd., Bantry, Cork (Irland) | Use of cis- (33Ä-trimethylcyclohexanol for the treatment of biliary diseases |
JPS5522616A (en) * | 1978-08-04 | 1980-02-18 | Tokyo Tanabe Co Ltd | Bile acid inclusion compound and injection containing the same |
US4264583A (en) * | 1979-07-25 | 1981-04-28 | The Procter & Gamble Company | Gallstone dissolution compositions and method |
JPS62153220A (en) * | 1985-12-27 | 1987-07-08 | Tokyo Tanabe Co Ltd | Water-based bile acid agent for internal use |
IT1245889B (en) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | PHARMACEUTICAL FORMULATIONS FOR ORAL USE GAS RESISTANT CONTAINING SALTS OF BILE ACIDS. |
-
1994
- 1994-08-16 DK DK94810472T patent/DK0640344T3/en active
- 1994-08-16 AT AT94810472T patent/ATE171874T1/en active
- 1994-08-16 EP EP94810472A patent/EP0640344B1/en not_active Expired - Lifetime
- 1994-08-16 ES ES94810472T patent/ES2121599T3/en not_active Expired - Lifetime
- 1994-08-16 DE DE59407041T patent/DE59407041D1/en not_active Expired - Lifetime
- 1994-08-24 CA CA002130787A patent/CA2130787C/en not_active Expired - Fee Related
- 1994-08-25 US US08/296,355 patent/US5534505A/en not_active Expired - Lifetime
- 1994-08-26 JP JP20232994A patent/JP3631782B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2208497A1 (en) | 2009-01-15 | 2010-07-21 | Charité-Universitätsmedizin Berlin (Charité) | Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient |
Also Published As
Publication number | Publication date |
---|---|
CA2130787C (en) | 2006-12-05 |
EP0640344B1 (en) | 1998-10-07 |
JPH0782150A (en) | 1995-03-28 |
JP3631782B2 (en) | 2005-03-23 |
EP0640344A1 (en) | 1995-03-01 |
DE59407041D1 (en) | 1998-11-12 |
DK0640344T3 (en) | 1999-07-05 |
ATE171874T1 (en) | 1998-10-15 |
US5534505A (en) | 1996-07-09 |
ES2121599T3 (en) | 1998-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2130787A1 (en) | Ursodeoxycholic acid-containing medicament in a liquid administration form | |
US4711906A (en) | Liquid diclofenac preparations | |
ZA200201904B (en) | Topical suspension formulations containing ciprofloxacin and dexamethasone. | |
EP1255557B1 (en) | Stable, nasally, orally or sublingually applicable pharmaceutical preparation containing desmopressin | |
UA73954C2 (en) | Levosimendan-containing solution for pharmaceutical use, particularly for intravenous administration | |
RU2001101892A (en) | TESTOSTERONE DERIVATIVE | |
ATE171952T1 (en) | PARATHORMONE FRAGMENTS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM | |
JPH0228121A (en) | Transmucosal absorbefacient and pernasal administering agent using the same absorbefacient | |
DE2818586C2 (en) | ||
US20220378803A1 (en) | Injectable compositions of ursodeoxycholic acid | |
US4837211A (en) | Spironolactone composition | |
US5955456A (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
US3144387A (en) | Anti-inflammatory compositions | |
WO1998043643A1 (en) | Aqueous acyclovir solution preparations | |
EP1108429A3 (en) | An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases | |
JPH0577648B2 (en) | ||
DE3942142A1 (en) | STABILIZATION OF GLYCOSYLATED T-PA | |
DE2443431A1 (en) | ANTIARTHRITIC AGENT | |
DE3942143A1 (en) | T-PA PRO STABILIZATION | |
KR950702528A (en) | N ^ G-monomethyl-L (L) -arginine hydrogen chloride derivatives and their use in the treatment of septic shock, (N ^ G-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK) | |
CN1190581A (en) | Complex rifampin injection | |
US3322627A (en) | Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor | |
RU2805311C1 (en) | Injectable compositions based on ursodeoxycholic acid | |
JPH11139970A (en) | Oral solution | |
JPH069430A (en) | Stable eye lotion compounded with lysozyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130826 |